AML exhibits significant genetic and molecular heterogeneity, with a complex range of gene mutations and chromosomal abnormalities, including key alterations in genes such as FLT3, NPM1, DNMT3A, and TP53 in AML patients (Ali and Salih, 2023). The gene discussed is TP53; the disease is acute myeloid leukemia.